Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from ...

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

Bristol Myers Squibb (NYSE: BMY) today reported first quarter 2026 financial results. Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed first quarter 2026 ...

Bristol Myers Squibb's valuation metrics show the stock is a bona fide bargain. However, valuation metrics can be misleading ...

After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...

Bristol Myers Squibb is proving its worth as an M&A competitor, coming out on top not once but twice in terms of fresh acquisitions. Most recently, the pharma’s $4.1 billion bid for ...

After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in a deal valued at up to $5.8 ...

India has mandated local production of EV truck electronics such as BMS and VCUs from September 2026. Only compliant vehicles ...